# **U**NOVARTIS

## KESIMPTA - How does KESIMPTA work

## Prescribing information

Image



Image



# How does KESIMPTA®▼ (ofatumumab) work?

KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.<sup>1</sup>


### For full safety information, please refer to the <u>KESIMPTA Summary of Product</u> <u>Characteristics (SmPC)</u>.<sup>1</sup>

KESIMPTA has been shown to act on B-cells in MS patients, targeting them and inducing cell lysis.<sup>1</sup> KESIMPTA is an anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody that

selectively targets and binds to the CD20 protein.<sup>1</sup> This protein is expressed on the surface of the majority of B-cells, making it a valuable target for precise MS treatment.<sup>2</sup> KESIMPTA is thought to work by selectively binding to sites on both the small and the large extracellular loops of CD20 protein on B-cells.<sup>2-4</sup>

The precise mechanism of action by which KESIMPTA exerts its therapeutic effects is unknown.

To learn about how KESIMPTA targets B-cell subsets that facilitate inflammation, and how it causes CD20-inducing lysis of these B-cells, watch this short video.<sup>1</sup>





CD, cluster of differentiation; IgG, immunoglobulin G; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

### **References:**

Image

- 1. KESIMPTA (ofatumumab) Summary of Product Characteristics.
- 2. Zhang B. *mAbs* 2009;1(4):326-331.
- 3. Gupta IV & Jewell RC. Ann N Y Acad Sci 2012;1263:43-56.
- 4. Martin R, et al. Eur J Immunol 2016;46:2078-2090.

Safety profile

UK | April 2025 | FA-11381598

Adverse events should be reported. Reporting forms and information can be found at <u>www.mhra.gov.uk/yellowcard</u>. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at <u>www.novartis.com/report</u>, or alternatively email <u>medinfo.uk@novartis.com</u> or call 01276 698370.

#### Source URL:

https://www.pro.novartis.com/uk-en/medicines/neuroscience/kesimpta/moa/mechanism-vid eo